Brought to you by 
P&G takes broad rights to Regeneron research
13 Jul 1999
Executive Summary
Procter & Gamble will support the bulk of Regeneron Pharmaceuticals' discovery research over 5 years ($75mm R&D plus up to $60mm in equity); the partners will collaborate for a second 5 years sharing expenses equally, unless either opts to withdraw.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
P&G takes broad rights to Regeneron research
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice